Moesin Expression in Clear Cell Renal Cell Carcinoma

Sohag University50 enrolled

Overview

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Renal Cell Carcinoma

Interventions

Immunohistochemical detection of Moesin in Clear cell Renal Cell CarcinomaGENETIC

Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. All cases of ccRCC. 2. Tissue blocks with material adequate for immunohistochemical evaluation. 3. All cases with accessible clinical data. Exclusion Criteria: 1. Cases of renal neoplasms other than ccRCC. 2. Patients who received preoperative chemotherapy or radiotherapy. 3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations. 4. Cases with insufficient/destructed material. 5. Patients with inadequate clinical data.

Outcomes

Primary Outcomes

Detection of Moesin in renal cell carcinoma

different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.